Study on AZD8205 Alone or with Other Cancer Drugs for Advanced or Metastatic Solid Tumors

Inclusion Criteria

• Must be 18 years or older.
• Have advanced or metastatic solid tumors that have been treated with standard therapies, or if a clinical trial is considered the best option by the doctor.
• Have measurable disease according to specific medical criteria.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.
• Have adequate organ and bone marrow function as defined in the study.

For Sub-Study 1 Part A:

• Have confirmed metastatic or locally advanced/recurrent breast, ovarian, biliary tract, or endometrial cancer.

For Sub-Study 1 Part B:

• Have confirmed metastatic or locally advanced and recurrent disease for specific cancer types:
  • Biliary Tract Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Endometrial Cancer

For Sub-Study 2 Part A:

• Weigh at least 30 kg.
• Have confirmed metastatic or locally advanced/recurrent breast, ovarian, biliary tract, or endometrial cancer.

Exclusion Criteria

• Have received certain cancer treatments within specific time frames before starting the study:
  • Nitrosourea or mitomycin C within 6 weeks.
  • Investigational drugs from a previous study within 5 half-lives or 28 days.
  • Other anticancer treatments within 21 days for cytotoxic drugs, 21 days or 5 half-lives for non-cytotoxic drugs, and 28 days for biological products.
• Have spinal cord compression or a history of cancer spread to the brain lining.
• Have untreated or unstable brain metastases.
• Have active infections like tuberculosis, hepatitis B or C, or HIV.
• Have a history of lung inflammation requiring steroids or current lung issues.
• Have severe lung problems from other illnesses.
• Have certain heart conditions, such as uncontrolled arrhythmias, recent heart attacks, or severe heart disease.
• Have a history of stroke or brain blood flow issues in the last 6 months.
• Have a prolonged QT interval on an ECG.
• Have risk factors for heart rhythm problems.

Additional Exclusion Criteria for Part A Sub-Study 2:

• Have had a blood clot within 3 months before starting the study.
• Have had severe side effects from previous immunotherapy.
• Have active or past autoimmune or inflammatory disorders requiring long-term steroid or immunosuppressive treatment.